Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of
the voltage-gated sodium channel. It is closely related to both carbamazepine and …

Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in
2009 by the European Medicines Agency (EMA)(Zebinix™), and in 2013 by the US Food …

OBJECTIVE: To investigate the efficacy and safety of once-daily eslicarbazepine acetate
(ESL) when used as add-on treatment in adults with≥ 4 partial-onset seizures per 4-week …

Objectives–To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as
adjunctive therapy in adults with partial‐onset seizures. Material and methods–Double …

Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Purpose: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive
therapy for refractory partial seizures in adults with≥ 4 partial‐onset seizures (simple or …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Partial epilepsy comprises simple partial seizures, complex partial seizures, and secondarily
generalized seizures, and covers more than 60% of patients with epilepsy. Antiepileptic …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Objective To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in
patients with refractory partial‐onset seizures. Methods This randomized, placebo …